Leukemia

Pivotal study leading to Gleevec's rapid approval for CML published

Published in Cancer Weekly, April 2nd, 2002

Researchers at the University of Texas M.D. Anderson Cancer Center have published the pivotal study that demonstrates the success of Gleevec (formerly STI-571) in treating chronic myelogenous leukemia (CML) patients who had failed standard therapy.

The study, along with two other studies in advanced CML phases, resulted in the drug's approval in one of the fastest reviews ever for a cancer therapy by the U.S. Food and Drug Administration (FDA) in May 2001.

Dr. Hagop Kantarjian, professor and chairman of M.D. Anderson's department of leukemia is the lead author of the international study, which is published in the February 28, 2002, issue of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-04-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry